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Department of Microbiology and Immunology, University of Vancouver, Vancouver, British Columbia, Canadae; J. Craig Venter Institute, San Diego, California, USAf; and
Department of Pathology, Harbor-UCLA Medical Center, Torrance, California, USAg
ABSTRACT New treatments are needed for extensively drug-resistant (XDR) Gram-negative bacilli (GNB), such as Acinetobacter
baumannii. Toll-like receptor 4 (TLR4) was previously reported to enhance bacterial clearance of GNB, including A. baumannii.
However, here we have shown that 100% of wild-type mice versus 0% of TLR4-deficient mice died of septic shock due to A. bau-
mannii infection, despite having similar tissue bacterial burdens. The strain lipopolysaccharide (LPS) content and TLR4 activa-
tion by extracted LPS did not correlate with in vivo virulence, nor did colistin resistance due to LPS phosphoethanolamine mod-
ification. However, more-virulent strains shedmore LPS during growth than less-virulent strains, resulting in enhanced TLR4
activation. Due to the role of LPS in A. baumannii virulence, an LpxC inhibitor (which affects lipid A biosynthesis) antibiotic
was tested. The LpxC inhibitor did not inhibit growth of the bacterium (MIC> 512g/ml) but suppressed A. baumannii LPS-
mediated activation of TLR4. Treatment of infected mice with the LpxC inhibitor enhanced clearance of the bacteria by enhanc-
ing opsonophagocytic killing, reduced serum LPS concentrations and inflammation, and completely protected the mice from
lethal infection. These results identify a previously unappreciated potential for the new class of LpxC inhibitor antibiotics to
treat XDR A. baumannii infections. Furthermore, they have far-reaching implications for pathogenesis and treatment of infec-
tions caused by GNB and for the discovery of novel antibiotics not detected by standard in vitro screens.
IMPORTANCE Novel treatments are needed for infections caused by Acinetobacter baumannii, a Gram-negative bacterium that is
extremely antibiotic resistant. The current study was undertaken to understand the immunopathogenesis of these infections, as
a basis for defining novel treatments. The primary strain characteristic that differentiated virulent from less-virulent strains was
shedding of Gram-negative lipopolysaccharide (LPS) during growth. A novel class of antibiotics, called LpxC inhibitors, block
LPS synthesis, but these drugs do not demonstrate the ability to kill A. baumannii in vitro. We found that an LpxC inhibitor
blocked the ability of bacteria to activate the sepsis cascade, enhanced opsonophagocytic killing of the bacteria, and protected
mice from lethal infection. Thus, an entire new class of antibiotics which is already in development has heretofore-unrecognized
potential to treat A. baumannii infections. Furthermore, standard antibiotic screens based on in vitro killing failed to detect this
treatment potential of LpxC inhibitors for A. baumannii infections.
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Toll-like receptor 4 (TLR4) is an archetypal pattern recognitionreceptor for lipopolysaccharide (LPS) from Gram-negative
bacilli (GNB) (1–3). In the absence of completely functional
TLR4, both mice and humans are more susceptible to lethal infec-
tion caused by a broad array of pathogenic GNB, including enteric
commensal organisms (e.g., Klebsiella pneumoniae and Esche-
richia coli), highly virulent nonenteric members of the Enterobac-
teriaceae (e.g., Salmonella), community Gram-negative pathogens
(e.g., Neisseria and Haemophilus), and nonfermenting GNB that
cause lethal nosocomial infections (e.g., Pseudomonas) (3–11).
Acinetobacter baumannii is a GNB that has emerged as one of
the most common and highly antibiotic-resistant nosocomial
pathogens in the United States and throughout the world (12–14).
The majority of such infections are now extensively drug resistant
(XDR) (i.e., resistant to carbapenems and all other antibiotics ex-
cept colistin or tigecycline) (15–22), and they are increasingly
nonsusceptible even to both colistin and tigecycline (12, 23–29).
Such pandrug-resistant (PDR) A. baumannii infections are resis-
tant to every U.S. Food and Drug Administration-approved anti-
biotic and are hence untreatable. Indeed, A. baumannii is one of
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the few bacterial pathogens that have become resistant to all avail-
able antibiotics.
With rising rates of resistance, A. baumannii infections
threaten to become progressively more lethal. In a recent study of
13,796 patients in 1,265 intensive care units (ICUs) from 75 coun-
tries, A. baumannii was 1 of only 2 of the 19 microorganisms
evaluated which were strongly linked (P 0.01) to increased hos-
pital mortality by multivariate logistic regression (30). Further-
more, the odds ratio for in-hospital mortality of A. baumannii
infections was 1.53, the highest for all GNB and in the top three
among all organisms. Infections caused by carbapenem-resistant,
XDR A. baumannii are associated with longer hospitalization,
greater health care costs, and higher mortality versus infections
caused by carbapenem-susceptible strains (12, 19, 21, 24, 31–35).
Bacteremia with sepsis syndrome is a common clinical syndrome
in patients with these infections, and bloodstream infections
caused by XDR A. baumannii caused50 to 60% mortality rates
(31 33, 34 36–38). Given their extreme resistance, rising fre-
quency, and high mortality rates, defining fundamental host-
pathogen interaction mechanisms for A. baumannii infections is
critical to future development of novel small-molecule and bio-
logical inhibitors of disease.
A. baumannii expresses immune-reactive LPS on its cell sur-
face (39). LPS from A. baumannii induces macrophage release of
tumor necrosis factor (TNF) and interleukin 8 (IL-8) in a TLR4-
dependent manner (40). In vivo, TLR4-deficient mice did not me-
diate an inflammatory response to intranasal A. baumannii LPS
(41). Furthermore, TLR4-deficient mice had slower clearance of
A. baumannii from lung parenchyma (41). Thus, the contempo-
rary understanding maintains thatA. baumanniiLPS-induced sig-
naling of TLR4 was critical for protecting the host against infec-
tion, as is true of many other GNB. However, the in vivo model
used in this previous study was nonlethal, and the outcome mea-
sured was slower clearance of bacilli.
The current study defines the role of innate immune mecha-
nisms and LPS stimulation during lethal A. baumannii infections.
Surprisingly, TLR4-mutant mice were not susceptible to and were
instead highly resistant to lethal infection caused byA. baumannii.
The distinguishing characteristic of more- or less-virulent A. bau-
mannii strains was the TLR4-stimulating activity of LPS shed dur-
ing growth, rather than the content of LPS per bacillus or the
intrinsic potency of TLR4-stimulating activity of extracted LPS.
Finally, small-molecule antibiotic inhibition of LPS synthesis de-
creased TLR4 activation and protected mice from lethal infection
even though the antibiotic did not kill the bacteria. These results
have fundamental implications for pathogenesis of infections
caused by GNB and for the discovery of novel therapeutics that are
not detected in standard in vitro antibiotic screens and suggest
new treatment strategies for XDR/PDR GNB infections.
RESULTS
A. baumannii-infected wild-type mice died of septic shock that
did not occur in TLR4-mutant mice. To determine the impact of
TLR4 deficiency on survival, C3H/FeJ (wild-type) and C3H/HeJ
(TLR4-defective mutant) mice were infected via the tail vein with
a highly virulent strain of XDR A. baumannii, HUMC1 (42), or a
second clinical isolate (and type strain), ATCC 17978, that is less
virulent in mice (42). HUMC1 induced 100% fatal infection in
wild-type mice but no mortality in TLR4-mutant mice (Fig. 1).
ATCC 17978 was nonlethal in both mouse strains (Fig. 1). The
same phenomenon was observed in TLR4-knockout (KO) mice
and congenic C57BL/6 wild-type controls infected with HUMC1
(Fig. 1).
Additional mice were infected to quantify sepsis biomarkers.
The initial experiments demonstrated that a substantial number
of control mice would begin to die on day 2 postinfection, making
it impossible to accurately measure sepsis biomarkers after day 2.
Prior to and on days 1 and 2 postinfection, rectal temperatures
were measured between 8 and 9 AM using a digital thermometer
(Physitemp, model BAT-12). Compared to the baseline, wild-type
mice infected with A. baumannii HUMC1 became profoundly
hypothermic during the first 2 days of infection, while TLR4-
mutant mice maintained normal body temperatures (Fig. 2A). At
day 2 postinfection (the day the control mice were anticipated to
begin dying), wild-type mice infected with HUMC1 became pro-
foundly acidemic (Fig. 2B) and had substantially higher levels of
the serum proinflammatory cytokines, TNF and IL-6, and the
counterregulatory, suppressive cytokine, IL-10, than did TLR4-
mutant mice (Fig. 2C). In both mouse strains, A. baumannii
ATCC 17978 induced lower levels of these cytokines, as well as
gamma interferon (IFN-), than did HUMC1 (Fig. 2C).
Despite marked differences in sepsis biomarkers and survival,
there were surprisingly small differences in tissue bacterial bur-
dens during infection between wild-type and TLR4-mutant mice
(Fig. 2D) A. baumannii HUMC1 infection resulted in trends to
higher blood and tissue bacterial burdens in wild-type versus
TLR4-mutant mice, but none of the differences were statistically
significant. The lower-virulenceA. baumannii strain ATCC 17978
resulted in lower bacterial burdens in blood and tissue than did
HUMC1, but the ATCC 17978 bacterial burden was similar in
wild-type versus TLR4-mutant mice. Thus, the difference in se-
verity of infection between wild-type and TLR4-mutant mice was
not related to alterations in clearance of the bacterial pathogen.
Histopathology revealed relatively normal parenchymal or-
gans. To determine if lethal infection was the result of differences
in organ invasion in HUMC1-infected mice, histopathology was
performed. Surprisingly, all parenchymal organs evaluated from
wild-type or TLR4-mutant mice infected with either HUMC1 or
ATCC 17978 had preserved, normal architecture with no evidence
of bacterial invasion or a host response to infection within the
organs (Fig. 3A). In spleens of all groups, neutrophil influx into
the perifollicular red pulp was seen (Fig 3A). In the lungs, no
FIG 1 TLR4 is antiprotective against A. baumannii bloodstream infection.
C3H/FeJ wild-type or C3H/HeJ TLR4-mutant mice (n  10 mice per group,
except for 9 mice in the wild-type HUMC1-infected group) or C57BL/6 or
congenic TLR4-knockout (KO) mice were infected via the tail vein with 2 
107 bacteria and followed for 28 days. All remaining mice at day 28 appeared
clinically well. *, P 0.05 versus results for all other groups.
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alveolar infiltrates were seen, but neutrophils were found in the
capillaries, consistent with capillaritis typical of LPS-induced sep-
sis syndrome (Fig. 3A). The kidneys appeared histologically nor-
mal. The histopathological findings were remarkably similar to
those seen in tissues that had been fixed during HUMC1 infection
in diabetic BALB/c mice from experiments previously reported
(42).
Immunohistochemistry was performed to localize the bacteria
in the organs. Consistent with the finding of extensive neutrophil
influx into the perifollicular red pulp, mice had extensive bacterial
infiltration localized to the perifollicular red pulp of the spleen
(Fig. 3B). Splenic lymph node follicles were spared. In the kidneys,
scattered bacterial influx was found localized to capillaries sur-
rounding renal tubules (Fig. 3B). Similarly, in the lung, bacteria
were found in interstitial capillaries (Fig. 3B). In none of the or-
gans was bacterial invasion into the parenchymal tissues found.
Thus, A. baumannii did not appear to be capable of invasion of
parenchymal organs during systemic infection.
LPS shedding distinguished more-virulent from less-
virulent strains of A. baumannii. The protection against lethal
infection afforded by mutant TLR4 and the localization of bacteria
to capillaries consistent with sepsis syndrome implicated LPS as a
primary pathogenesis factor of A. baumannii. A panel of clinical
isolates of A. baumannii (Table 1) was compared for in vivo viru-
lence so that more- and less-virulent strains could be compared
for LPS bioactivity. Pilot studies demonstrated that five XDR clin-
ical isolates (HUMC4, -5, -6, and -12) (Table 1) (42) were aviru-
lent at the 2  107 inoculum at which the HUMC1 strain was
100% fatal. Thus, a higher inoculum (5 107) was tested, at which
HUMC4, -5, -6, and -12 caused 100% fatal infection within 4 days,
while ATCC 17978 remained nonlethal (Fig. 4A). Two colistin-
resistant clinical isolates with defined LPS mutations causing
FIG 2 Lethally infected wild-type mice had septic shock, whereas TLR4-mutant mice did not. (A) Rectal temperatures taken from mice infected with
A. baumannii HUMC1 or ATCC 17978 (the same mice in Fig. 1; n 10 mice per group, except for 9 in the wild-type HUMC1-infected group). Temperatures
were taken at the same time (8 to 9 AM) daily before and for 2 days after infection (wild-type mice began dying on day 2). *, P 0.05 versus preinfection findings.
(B) Blood pH at 48 h of infection was measured by using i-STAT cartridges from separate C3H/FeJ or C3H/HeJ (TLR4-mutant) mice infected with 2  107
A. baumanniiHUMC1 or ATCC 17978 bacteria (n 16 mice per group from 2 experiments, except for 8 mice for HUMC1-infected wild-type mice). *, P 0.05
versus results for other groups. (C) Serum inflammatory and anti-inflammatory cytokine levels were measured at 48 h of infection in C3H/FeJ or C3H/HeJ
(TLR4-mutant) mice. n 8 mice per group. **, P 0.05 versus results for all other groups; *, P 0.05 versus results for ATCC 17978 groups. (D) Blood and
tissue bacterial burden at 48 h of infection differed between mice infected with 2  107 HUMC1 and ATCC 17978 bacteria (n  12 mice per group from 2
experiments) but not between mutant and wild-type mice. *, P 0.05 versus results for mice infected with ATCC 17978. Median and interquartile ranges are
graphed.
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changes to lipid A (R2 and C14) (Table 1) (43), were tested as well.
The colistin-resistant C14 (pmrB160) clinical isolate, isolated
from the wound of a Brazilian patient, caused rapid, lethal infec-
tion. In contrast, the other colistin-resistant strain, R2
(pmrBT235I), caused no mortality (Fig. 4A). Growth curves dem-
onstrated similar growth rates for all of these strains (Fig. 4B), so
growth rates did not account for differences in virulence.
Total LPS content (ng LPS/bacillus) was found to be similar
when comparing strains with high versus low virulence (e.g.,
HUMC1 versus ATCC 17978 versus R2) (Fig. 5A). Thus, there was
no apparent relationship between LPS density and strain virulence
in vivo. LPS extracted from each strain was tested for intrinsic
TLR4-activating potency using HEK-Blue cells transfected with a
TLR4-linked colorimetric reporter gene. The highest TLR4 acti-
FIG 3 Histopathology and immunohistochemistry of A. baumannii during
infection in mice. (A) Histopathology of spleens, lungs, and kidneys from
C3H/FeJ mice given lethal infection with A. baumannii HUMC1 (2  107
inoculum) demonstrated normal parenchymal anatomy, with no evidence of
bacterial invasion (100 power shown). At higher power (600), the only
abnormalities found were accumulation of neutrophils (asterisks), including
pyknotic neutrophils (arrows) undergoing nucleolysis consistent with apopto-
sis, in the splenic perifollicular red pulp area and in the pulmonary capillaries,
consistent with Gram-negative LPS-induced sepsis. The kidney appeared his-
topathologically normal at higher power (not shown). (B) Immunohisto-
chemistry was used to localize A. baumannii in parenchymal organs. In the
spleen, the bacteria accumulated in the perifollicular red pulp areas and spared
lymph node follicles (note green spots surrounding dark follicles). In the kid-
neys, the organisms were found scatted in capillaries surrounding renal tu-
bules, and there was no evidence of parenchymal organ invasion. In the lung,
the organisms were found in capillaries in the interstitium, and again there was
no evidence of alveolar or parenchymal invasion from the capillaries. The
control was stained with normal mouse serum as the primary antibody.
TABLE 1 Strains useda
Strain Source and comments (reference)
ATCC 17978 Isolated from cerebral spinal fluid in 1951 from a 4-mo-old with fatal meningitis (61)
HUMC1 Blood and sputum clinical isolate
HUMC4 Deep endotracheal aspirate clinical isolate
HUMC5 Bronchoalveolar lavage clinical isolate
HUMC6 Sputum clinical isolate
HUMC12 Wound infection clinical isolate
R2 Laboratory-derived colistin-resistant mutant derived by serial passage of ATCC 1798 in colistin; pmrBT235I
C14 Polymyxin-resistant clinical isolate
a HUMC strains are described in reference 42; R2 and C14 are described in reference 43.
FIG 4 Various virulences of clinical isolates, including colistin-resistant
strains. (A) C3H/FeJ mice were infected iv with 5 107 HUMC4, -5, -6, and
-12 and R2 and C14 bacteria, all of which caused 100% mortality (n 5 to 8
mice per group). ATCC 17978 and R2 were avirulent. (B) In vitro growth rates
did not differ substantially among strains irrespective of virulence in vivo.
Lin et al.
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vation in extracted LPS was found in the C14 colistin-resistant
strain of A. baumannii, which had activity comparable to that of
LPS extracted from E. coli (Fig. 5B). Of the colistin-susceptible
strains, the highest TLR4-activating potency was found in LPS
extracted from the least-virulent strain, ATCC 17978 (Fig. 5B).
Intriguingly, the other hypovirulent strain, R2, which has a single
point mutation in the regulatory gene pmrB that leads to upregu-
lation of pmrC and decoration of lipid A of LPS by phosphoetha-
nolamine (43), led to a nearly 2-fold increase in LPS proinflam-
matory potency, to a level almost the same as that of C14, which
also had upregulated pmrC. Thus, intrinsic TLR4-activating po-
tency of LPS extracted from each strain appeared to be related to
the dysregulation of pmrC that caused polymyxin resistance, but it
did not correlate with virulence.
Since LPS density per bacillus and TLR4-activating potency of
extracted LPS did not correlate with in vivo virulence, shedding of
LPS during growth was analyzed. Culture supernatants from cells
at the mid-logarithmic phase of growth were filter sterilized (con-
firmed by no growth in the cultured filtrate) and tested in the
TLR4 activation assay. Culture supernatants from the most viru-
lent strains, HUMC1 and C14, were by far the most potent at
inducing TLR4 activation and came the closest to the potency of
E. coli culture supernatant (Fig. 5C). Boiling of the supernatants or
exposure to proteinase K did not alter TLR4 activation (data not
shown), implicating a heat-stable, nonproteinaceous inflamma-
tory inducer (such as LPS). Furthermore, polymyxin abrogated
TLR4 activation by the supernatants of all strains except the
colistin-resistant strain, C14 (the LPS of which, it being a
polymyxin-resistant isolate, would not bind well to polymyxin),
confirming that TLR4 activation was due to LPS. Finally, the lim-
ulus amebocyte lysate assay confirmed that despite the substantial
intrinsic TLR4-activating potency of their extracted LPS, the LPS
activity in culture filtrates from ATCC 17978 and R2 was lower
than that from the other strains, consistent with their reduced
virulence.
Inhibition of LPS biosynthesis did not killA. baumannii but
enhancedopsonophagocytosis anddecreased inflammation, re-
sulting in protection of mice from lethal infection. Small-
molecule inhibitors of a key enzyme, LpxC, involved in the first
committed step in the synthesis of LPS lipid A, are in advanced
preclinical development as antibiotics (44, 45). These agents have
broad activity against GNB, but most do not have in vitro killing
activity against A. baumannii and therefore have been assumed to
be incapable of treating A. baumannii infections and have not
been studied for this purpose. Nevertheless, based on the correla-
tion between LPS shedding and strain virulence, an investigational
LpxC inhibitor that is in advanced preclinical development,
LpxC-1, was obtained for testing. LpxC-1 had no detectable MIC
when tested against the HUMC A. baumannii strains at concen-
trations up to 512g/ml. Nevertheless, overnight growth followed
by a 3-h passage of the A. baumannii strains in the presence of 4
g/ml of LpxC-1 resulted in diminished TLR4-activating potency
FIG 5 In vitro correlate of in vivo virulence. (A) LPS content (ng/bacillus) was similar across strains of highly varying virulences (e.g., HUMC1 versus ATCC
17978 versus R2). Results are from at least two separate extractions, each done in duplicate. (B) TLR4-activating potency of extracted LPS was higher for R2 and
C14 than all other A. baumannii strains (**, P  0.05 versus results for all other strains except E. coli). Of the colistin-susceptible A. baumannii strains,
TLR4-activating potency was highest among A. baumannii ATCC 17978, which was avirulent (*, P 0.05 versus HUMC strains). Results are from a minimum
of two assays per strain, each done in duplicate. (C) Filter-sterilized culture supernatant induced a much stronger TLR4 signal from strains that caused lethal
infections in vivo than from avirulent strains. Also, addition of polymyxin blocked the TLR4 activation from all strains except those highly resistant to colistin (C8
and C14), which were not affected by polymyxin. Results are from a minimum of three assays per strain, each done in duplicate. For all panels, median and
interquartile ranges are graphed.
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of the culture supernatant as well as that of LPS extracted from the
bacilli (Fig. 6A).
Exposure of bacteria to LpxC-1 prior to tail vein infection in
mice, followed by treatment of the mice with LpxC-1, completely
protected them from lethal infection (Fig. 6B). Subsequently,
mice were infected with A. baumannii HUMC1 grown overnight
and passaged to log phase without exposure to LpxC-1, and treat-
ment with LpxC-1 was initiated after infection. Treatment of es-
tablished infection was also completely protective (Fig. 6C). To
determine the efficacy of LpxC-1 in a compromised host model,
neutropenic mice were infected with A. baumannii and treated
with LpxC-1 or the placebo. LpxC-1 markedly improved survival
of neutropenic mice (Fig. 6D).
The impact of LpxC-1 on bacterial density and cytokine pro-
duction in C3H/FeJ mice was determined. Infected mice were
treated with LpxC-1 and euthanized at 24 or 48 h postinfection to
harvest blood and organs. The infection was substantially lethal,
resulting in deaths of 5 of the 15 control mice before the 24-h time
point. No LpxC-1-treated mice died. At 24 h, LpxC-1-treated
mice had a 500-fold reduction in median blood and tissue bacte-
rial densities (Fig. 7A), as well as a median 600-fold reduction in
serum LPS (Fig. 7B) and 10- to 100-fold reductions in median
levels of serum proinflammatory cytokines (e.g., IFN-, IL-12,
IL-1, IL-6, TNF-, and KC) and the anti-inflammatory cytokine
(IL-10) (Fig. 7C). By 48 h, only 2 control mice were alive, but
similar trends were seen in the differences between bacterial den-
sity and serum LPS and cytokine levels (data not shown). Blood
bacterial density and serum LPS concentrations correlated for
placebo-treated mice (P 0.008) but not for LpxC-1-treated mice
(Fig. 7B). Also, placebo-treated mice had a 90-fold-higher median
ratio of serum LPS concentration to blood bacterial density than
did LpxC-1-treated mice (P 0.001) (Fig. 7B).
Finally, to determine how LpxC-1 could alter in vivo bacterial
density even though it did not kill the bacteria in vitro, we com-
FIG 6 Inhibition of LPS biosynthesis with an inhibitor of LpxC blocked TLR4
activation in vitro and abrogated virulence in vivo. (A) TLR4-activating po-
tency of filtered culture supernatant and extracted LPS from A. baumannii
strains passaged to log phase in the presence of 4 g/ml of LpxC inhibitor
(LpxC-1). The results with LpxC-1 were run concurrently with those without
LpxC-1 (compare signal with and without LpxC-1 inhibitor in Fig. 5C versus
Fig. 6A). (B) Survival of wild-type C3H/FeJ mice (n  10 per group) which
were either infected with normal A. baumannii HUMC1 and treated with a
placebo (40% cyclodextrin in water i.v. once daily) for 3 days starting on the
day of infection or infected with A. baumannii HUMC1 that was cultured
overnight and during log passage in the presence of 4g/ml of LpxC inhibitor
and treated with LpxC-1 (100 mg/kg in 40% cyclodextrin i.v.) for 3 days
postinfection. (C) Survival of wild-type C3H/FeJ mice (n  10 per group)
which were infected with A. baumannii HUMC1 and treated with a placebo
(40% cyclodextrin in water) or LpxC-1 (100 mg/kg in 40% cyclodextrin i.v.)
starting 1 h after infection and for 3 days postinfection. (D) Survival of BALB/c
mice (n 11 in the placebo group; n 10 in the LpxC1-treated group) made
neutropenic with cyclophosphamide, infected with A. baumannii HUMC1,
and treated with placebo or LpxC-1 starting after infection and for 3 days
postinfection.
FIG 7 Bacterial densities in blood and tissue and serum LPS and cytokine
concentrations for mice treated with LpxC-1 or a placebo. C3H/FeJ mice (n
15 per group) were infected with A. baumannii HUMC1. At 1 h and 24 h,
infected mice were treated i.v. with LpxC-1 (100 mg/kg). Five control mice
died before the 24-h time point; no treated mice died. (A) Bacterial densities in
blood and tissue for treated versus control mice. (B) Serum LPS levels for
treated versus control mice. (C) Serum cytokine levels for treated versus con-
trol mice. *, P 0.01 versus results for the control.
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pared MICs of LpxC-1 with and without serum and found no
change in MICs in the presence of serum. Since LpxC-1 did not
affect complement susceptibility of the bacteria (i.e., no growth
inhibition in the presence of serum or change in LpxC-1 MIC in
the presence of serum), we compared macrophage killing of bac-
teria in the presence or absence of LpxC-1. Exposure of A. bau-
mannii HUMC1 to LpxC-1 during the 1-h coincubation with
RAW cells resulted in a marked increase in macrophage killing of
the bacteria (Fig. 8). Preexposure of the macrophages to LpxC-1
for 1 h, followed by rinsing away the LpxC-1, did not affect mac-
rophage killing of the bacteria.
DISCUSSION
The finding that LPS-TLR4 interactions govern in vivo virulence
of A. baumannii and that an LpxC inhibitor antibiotic with no in
vitro activity against A. baumannii protected mice from lethal in-
fection are of considerable biological and translational impor-
tance. The protection despite a similar tissue bacterial burden but
with reduced inflammatory cytokines in TLR4-mutant mice dem-
onstrates that protection was driven by immunomodulation
rather than by altering the bacterial density of infection. Interest-
ingly, despite the lack of detectable in vitro killing of A. baumannii
by LpxC-1 in standard susceptibility tests, treatment of mice with
LpxC-1 markedly reduced tissue bacterial density, serum LPS lev-
els, and serum inflammatory cytokine levels. As a result, LpxC-1
totally protected mice from lethal infection. Exposure of bacteria
to the LpxC-1 inhibitor increased their susceptibility to op-
sonophagocytic killing by macrophages. The LpxC-1 inhibitor
also reduced the LPS levels in serum relative to the bacterial den-
sity in blood, so the effect on reducing immunopathogenesis was
greater than would be expected to be caused by another antibiotic
that reduced CFU without reducing LPS density in the bacteria.
Since LpxC inhibitors are already in advanced preclinical devel-
opment, these results indicate that such inhibitors should be
tested clinically in patients infected withA. baumannii irrespective
of in vitro susceptibility results. Since there are few if any drugs in
development with the potential to treat lethal XDR/PDR A. bau-
mannii infections, the discovery that an entirely new class of com-
pounds has therapeutic potential is of great potential clinical im-
portance. Furthermore, the colistin-mediated in vitro
neutralization of LPS activation of TLR4 suggests that adjunctive
colistin therapy, potentially at lower and hence less-toxic doses
than are typically used clinically, could reduce A. baumannii vir-
ulence in vivo irrespective of bactericidal activity. Thus, low-dose
colistin merits study as an adjunctive, combination therapy even
for A. baumannii strains that are susceptible to -lactam antibiot-
ics.
While colistin-resistant strains ofA. baumannii are reported to
have reduced virulence in mice (46), the current findings indicate
that colistin resistance does not necessarily intrinsically affect vir-
ulence. Indeed, several publications have defined varying strain
virulences unrelated to colistin resistance (47, 48). In the current
study, two strains with regulatory mutations affecting polymyxin
resistance through addition of phosphoethanolamine to LPS (43),
C14 and R2, were found to have highly divergent in vivo viru-
lences. The clinical isolate C14 was as virulent in vivo as
carbapenem-resistant, colistin-susceptible HUMC isolates. In
contrast, R2 was avirulent. Extracted LPS from both strains led to
enhanced TLR4 stimulation relative to that with LPS extracted
from other, non-colistin-resistant strains. However, the pmrC
mutation in R2 did not increase its LPS shedding relative to that of
its hypovirulent parent strain, 17978, and thus its virulence was
not affected. In contrast, strain C14 had both increased TLR4 ac-
tivation from extracted LPS and a very high level of LPS shed
during growth, resulting in enhanced in vivo virulence. The mo-
lecular genetics and structure of LPS that result in greater shed-
ding by the more-virulent strains merits investigation, since elu-
cidating these factors should result in novel targets for therapeutic
intervention.
These results also provide direct experimental confirmation of
the host-pathogen damage model of Casadevall and Pirofski (49).
Specifically, the A. baumannii bacterial burdens were similar dur-
ing lethal and nonlethal infection in wild-type versus mutant
mice, and evaluation of bacterial burden or clearance did not de-
scribe virulence for this pathogen. Rather, virulence was related to
induction of host hyperinflammation resulting in lethal sepsis.
Thus, investigation of infections caused byA. baumannii, whether
preclinical or clinical, should focus as much on host response bio-
markers as on microbiological eradication. Furthermore, caution
must be exercised when evaluating the severity of infection in
experimental models based solely on microbial burden. Microbial
burden may not accurately reflect “damage” to the host, or actual
outcome of infection, particularly in models that do not assess
actual physiological consequences of infection (e.g., nonlethal
models). For example, in a previous study, TLR4-KO mice on a
C57BL/6 background were reported to be susceptible to A. bau-
mannii infection, which may appear to be discordant with our
results. However, the previous study used a nonlethal model of
infection and found slower early clearance of the organism from
the lung (41). By 48 h, the organism had been cleared similarly by
wild-type and TLR4-KO mice, and there was no apparent clinical
or physiological consequence for the mice of this slower initial
bacterial clearance. Our data also showed a nonsignificant, mod-
estly lower bacterial burden in tissue of C3H/HeJ TLR4-mutant
mice than in wild-type mice and demonstrate that the clinical
outcomes were not driven by the tissue bacterial burden but rather
by the host response to the bacteria. Thus, our data are not discor-
dant from those of the previous study and must be interpreted in
the context of lethal versus nonlethal models.
FIG 8 Macrophage killing of A. baumannii is enhanced by exposure to
LpxC-1. Reduction of CFU at 1 h of A. baumannii incubation with LpxC-1
alone, macrophages alone, macrophages that had been preexposed to LpxC-1
for 1 h followed by rinsing away the LpxC-1, and macrophages plus LpxC-1.
Median and interquartile ranges of killing are shown. Results from are from
eight samples per group. *, P 0.05 versus results for LpxC-1 alone; **, P
0.05 versus results for all other groups.
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How the LpxC-1 inhibitor enhances phagocytosis is not clear.
The effect was not due to a direct impact of LpxC-1 on macro-
phages, because pretreatment of macrophages with the LpxC-1
inhibitor, followed by rinsing away the inhibitor, resulted in no
substantive change in macrophage killing of the bacteria. Muta-
tion of Lpx is known to result in upregulation of genes responsible
for the biosynthesis of poly--1,6-N-acetylglucosamine (PNAG),
which presumably replaces LPS as a predominant oligosaccharide
in the outer membrane, enabling the bacteria to maintain cell
viability (50). It has long been known that the macrophage man-
nose receptor binds to N-acetylglucosamine (51), which may ac-
count for the enhanced phagocytosis of A. baumannii in the set-
ting of LpxC-1 exposure.
Antimicrobial discovery screens and development programs
are typically built around lead compounds with low in vitroMICs,
preferably with microbicidal activity, against target bacteria.
However, such screens fail to detect the potential for antimicrobial
drugs to modulate pathogenesis aside from microbicidal activity
against the organism. Most LpxC inhibitors, including LpxC-1, do
not have in vitro activity againstA. baumannii by standard suscep-
tibility testing. However, A. baumannii is known to express LpxC
(52), and the current study demonstrates that while the LpxC
inhibitor tested did not inhibit A. baumannii growth, it did mark-
edly modulate the ability of the cells to activate TLR4 and induce
septic shock in vivo. These data underscore the importance of
finding new, physiologically relevant ways to screen for small-
molecule and biological agents to treat XDR/PDR GNB and other
highly resistant microbes in order to discover novel therapeutic
classes.
Bacteremia is one of the most common clinical syndromes
caused by A. baumannii and is often accompanied by sepsis syn-
drome (15, 18, 53–55). Such infections typically occur in patients
hospitalized in the ICU, most likely via bolus entry from catheters,
which is similar to the mode of entry in the model studied. An
advantage of the C3H model of infection is that relatively low
inocula (e.g., 2 107) induce fatal infection even without having
to cause overt immunocompromise. This lethal inoculum is sim-
ilar to that required to cause fatal infections by other virulent
bacteria in noncompromised mice, such as Staphylococcus aureus,
Enterococcus, and Pseudomonas aeruginosa (56, 57). In contrast,
the same inoculum of A. baumannii in other mouse models, such
as BALB/c mice, is nonfatal unless accompanied by induction of
diabetes mellitus or neutropenia (42, 58, 59).
In summary, LPS-mediated activation of TLR4 was a primary
pathogenic factor during systemic A. baumannii infection, and
TLR4 was antiprotective against lethal infection. Of great transla-
tional importance is that inhibition of LpxC resulted in dimin-
ished LPS-mediated TLR4 activation and protected mice from
lethal infection despite a lack of in vitro susceptibility of the bac-
teria to the inhibitor by traditional testing. These results under-
score the urgent and pressing need to find in vitro screens that
predict in vivo efficacy in a physiological way and the potential for
small-molecule and biological therapies to be effective antibacte-
rial agents even if they do not directly kill the target pathogen.
MATERIALS AND METHODS
Strains and mouse model of infection. Nine clinical isolates of A. bau-
mannii were used (Table 1). Wild-type (C3H/FeJ) and TLR4-mutant
(C3H/HeJ) mice and congenic C57BL/6 and congenic TLR4-knockout
(KO) mice were used (Jackson Laboratories). In some experiments,
BALB/c mice were made neutropenic using cyclophosphamide
(200 mg/kg of body weight given intraperitoneally [i.p.] on day2 rela-
tive to infection, with a repeat dose of 150 mg/kg 5 days later), as we have
previously described (58). A. baumannii strains were grown overnight at
37°C with shaking in tryptic soy broth (TSB). The bacteria were passaged
to mid-log-phase growth at 37°C with shaking. Cells were washed twice
with phosphate-buffered saline (PBS) and resuspended at the appropriate
concentration for infection. Infections with 2  107 or 5  107 bacteria
were administered intravenously (i.v.) via the tail vein. The final concen-
tration was confirmed by quantitative culturing of the inocula. The LpxC
inhibitor LpxC-1 (Pfizer Inc.) was dissolved in 40% cyclodextrin in sterile
water. Mice were treated subcutaneously with 100 mg/kg/day for 3 days
starting on the day of infection, based on previously published pharma-
cokinetic information for related compounds (45). Control mice were
treated with placebo (40% cyclodextrin in sterile water) alone. All animal
experiments were approved by the Institutional Committee on the Use
and Care of Animals at the Los Angeles Biomedical Research Institute,
following the National Institutes of Health guidelines for animal housing
and care.
Organ histopathology and immunofluorescence. Organs were fixed
in zinc-buffered formalin, embedded in paraffin, sectioned, and stained
with hematoxylin and eosin (H&E) or stained by immunofluorescence.
For immunofluorescence, the slides were deparaffinized and stained with
immune sera from mice surviving previous sublethal infection with
HUMC1 (convalescent-phase serum obtained 1 month after infection)
and counterstained with goat anti-mouse, fluorescein isothiocyanate
(FITC)-conjugated IgG.
Cytokine and sepsis biomarkers. Mice were sedated with ketamine,
and blood was obtained by cardiac puncture. Serum cytokines were quan-
tified by the MSD Multi-Spot assay (Mesoscale) per the manufacturer’s
instructions. Whole-blood pH was analyzed using the i-STAT system. For
experiments in which i-STAT measurements were made, it was necessary
to anticoagulate the mice with intraperitoneal heparin (100 U given i.p.;
Sigma-Aldrich, St. Louis, MO) simultaneously with sedation by intraperi-
toneal ketamine (100 mg/kg) 5 to 15 min prior to cardiac puncture to
prevent clotting in the i-STAT cartridges. Whole blood was aspirated into
a 25-gauge syringe and aliquoted into i-STAT cartridges. Values were read
on an i-STAT portable clinical analyzer. To measure serum LPS levels, the
limulus amebocyte assay (LAL) was used (Associates of Cape Cod, East
Falmouth, MA).
Temperature was measured using a digital thermometer, Physitemp
model Bat-12 (Physitemp Instruments Inc., Clifton, NJ). The probe was
inserted rectally to its hilt and maintained in this position until the tem-
perature reading stabilized. Temperature and weights were recorded be-
tween 8 and 9 AM each day.
TLR4 assay. A. baumannii strains were grown overnight at 37°C with
shaking in TSB. The bacteria were passaged at 37°C with shaking. Cells
were washed three times with PBS and resuspended to an optical density
of 1.0. LPS was isolated fromA. baumannii strains using an LPS extraction
kit (iNtRON Biotechnology, Inc.).
Each passaged strain was plated in TSB agar to determine the amount
of LPS per bacillus. Isolated LPS was stored in polystyrene tubes at 4°C,
and these were assayed for LPS activity within 1 month. For collection of
culture supernatants, the bacteria were passaged to an optical density of
1.5 at 37°C with shaking. The cultures were spun down at 4,000 rpm for
10 min, and supernatants were sterile filtered using 0.22-m syringe filters
(Millipore Corp.). To verify that there were no live cells in the filtered
supernatants, the supernatants were plated in TSB agar.
Dilutions of filter-sterilized culture supernatant and isolated LPS were
made in sterile glass tubes. The filtered supernatants and isolated LPS were
then assayed for TLR4 activity using the HEK-Blue LPS detection kit (In-
vivoGen). HEK-Blue-4 cells were passaged in HEK-Blue selection me-
dium until they were 60 to 80% confluent. Right before an assay, the cells
were washed with PBS to remove the selection medium and then diluted
to 2  105 cells/ml in HEK-Blue detection medium. In each well of a
Lin et al.
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96-well plate, 20 l of sample, 100 l of cells, and 100 l of HEK-Blue
detection medium were added. The plate was incubated for 18 h at 37°C in
5% CO2 and read using a spectrophotometer (BioTek Instruments, Inc.)
at 630 nm. For some experiments, bacteria were grown overnight and
passaged to log phase in the presence of 4g/ml of LpxC-1 before extrac-
tion of LPS or harvesting of supernatant. For other experiments, poly-
myxin B (Sigma-Aldrich) was added to TLR4 assay test wells to block LPS
effects or supernatants were boiled at 100°C for 20 min to determine the
impact of this on TLR4 activation.
Growth curves. A. baumannii strains were cultured overnight in TSB
at 37°C, passaged by placing 100 l of overnight culture in 10 ml of TSB,
and serially sampled to determine optical density and bacterial density by
quantitative culturing. Optical density was measured at an absorbance of
600 nm (Implen OD600 DiluPhotometer).
Killing assay. Bacterial killing by macrophages was assessed using our
previously published method (60). In brief, RAW 264.7 macrophage cells
(both from American Type Culture Collection, Rockville, MD) were cul-
tured at37°C in 5% CO2 in RPMI 1640 (Irvine Scientific, Santa Ana, CA)
with 10% fetal bovine serum (FBS), 1% penicillin, streptomycin, and
glutamine (Gemini Bioproducts), and 50 M -mercaptoethanol
(Sigma-Aldrich, St. Louis, MO). RAW cells were activated by 3 days of
exposure to 100 nM phorbol myristate acetate (PMA) (Sigma-Aldrich).
Activated RAW 264.7 macrophages were harvested after scraping with BD
Falcon cell scrapers (Fischer Scientific) and cocultured in polystyrene
snap cap tubes in a rotating drum at 37°C at a ratio of 20 bacteria to 1
macrophage. After a 1-h incubation, the tubes were sonicated and quan-
titatively plated in tryptic soy agar (TSA). Colony-forming units (CFU) of
the cocultured tubes were compared to CFU of growth control tubes
containing only microbes with no macrophages. Percent killing was cal-
culated as 1  (CFU from coculture tubes/CFU from growth control
tubes).
Statistics. Survival was compared by using the nonparametric log rank
test. Categorical variables were compared using the Wilcoxon rank-sum
test for unpaired comparisons or the Wilcoxon signed-rank test for paired
comparisons.
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